In The News: Department of Brain Health
AB Science is initiating a Phase 3 trial to evaluate the safety and efficacy of its candidate therapy masitinib in patients with mild to moderate Alzheimer’s disease.
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Alzheimer’s disease is a progressive neurological disorder that leads to brain atrophy and death of its cells. It is the most common cause of dementia. It leads to a persistent decrease in the ability to think, and in behavioral and social skills; This limits a person’s ability to live independently.
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.
An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
NervGen is developing a novel drug candidate that could revolutionise treatment for conditions associated with central nervous system damage, including Alzheimer’s disease.
The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.
The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.
Right now, Nevada has the third-fastest rate of growth for Alzheimer’s disease. Between now and 2025, the number of Nevadans with dementia is expected to grow almost 31% from 49,000 to 64,000.
The test, which measures β-amyloid in cerebrospinal fluid, received FDA de novo classification, making it the first IVD available for detection of brain amyloid plaques.